For the team at Cision Vision, 2023 has been a year of remarkable progress and innovation, especially with our flagship device – Cision InVision Imaging System. Reflecting on these milestones fills us with pride and reinforces our commitment to the anatomic pathology community and the broader medical field.
Key Achievements of 2023
Our journey this year has been marked by several key accomplishments:
- Customer-Centric Innovations:
We’ve made significant improvements to Cision InVision, reducing its size from 12” to a more compact 9”. This redesign enhances its functionality at grossing stations, making it more user-friendly and efficient. - Achievement of Multiple Certifications:
We have been diligent in maintaining the highest standards of quality and safety, and have successfully achieved and upheld major certifications, including ISO-13485, IEC, FCC, and EMC. - Recognition for Excellence:
Our efforts were acknowledged on prestigious platforms. Cision InVision received the Red Dot Award 2023 and was named in TIME’s Best Inventions of 2023. - Media Spotlight:
Our innovations have attracted significant media attention. Notably, The Pathologist Ad magazine featured Cision InVision in-depth, highlighting its revolutionary impact in digital pathology. - Active Community Engagement:
We actively participated in several AAPA conferences. A crowning moment was presenting our Cision InVision Imaging System at the White House Demo Day, attended by President Biden, and underlining our commitment to the pathology community - Groundbreaking Luminary Study Program:
Preliminary results from our study are promising, indicating a 97% increase in lymph node count and adjustments in cancer stages for 4.5% of cases. - Expanding Commercial Reach:
The early adoption of our Cision InVision device across leading U.S. institutions marks a significant commercial achievement, showcasing its effectiveness and reliability in busy grossing labs. - Global Expansion:
We concluded the year by expanding internationally, beginning with a collaborative effort in Switzerland, with distribution to multiple EU countries in the near future.
Looking Forward to 2024
As we step into 2024, our enthusiasm and dedication to enhancing cancer care and grossing performance remain unwavering. We are profoundly thankful for the support from the PA community and are excited to continue this journey together.
Dr. Jeremy Li, CEO and Co-Founder of Cision Vision, reflects on the year, stating, “We’re immensely grateful for the incredible journey 2023 has been. We’re eagerly anticipating an even more promising 2024 with updated features and options for Cision InVision coming soon. Our focus on customer feedback led us to redesign the device for better integration into laboratory workflows.”
About Cision Vision
The Cision InVision Imaging System stands at the forefront of technological innovation in pathology. This optical imaging tool revolutionizes how PAs identify lymph nodes, offering enhanced imaging contrast without the need for dyes, fluorescent tags, or radiation. Its real-time, high-contrast depiction of lymph nodes against adipose tissue marks a significant advancement in laboratory practice, aiding in the accurate staging of cancers and ultimately improving patient outcomes
As we continue to push the boundaries of grossing performance, we remain committed to our mission of transforming pathology practice and cancer care on a global scale. To schedule an on-site demo, or to see a virtual presentation please contact us today!